PeptideLabs Logo
PeptideLabs
All profiles

CJC-1295 no DAC

Peptide · Endocrine signals

Distinguished online from the DAC version and discussed for growth-hormone signalling; approval and confirmed safety are lacking.

Not FDA/EMA approvedWADA
LibraryNo account · this device only

Also known as: CJC-1295 without DAC · Modified GRF 1-29 · Mod GRF

Use at a glance

CJC-1295 no DAC

Distinguished online from the DAC version and discussed for growth-hormone signalling; approval and confirmed safety are lacking.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
100 µg
How often?
once per day
What time of day?
fasted before sleep
What period?
Week 1–2
How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
View preparationCheck sources
Overview of all entries

  • CJC-1295 no DAC · Week 1–2

    Online report · not medically verified

    100 µg · once per day · fasted before sleep

  • CJC-1295 no DAC · Week 3–4

    Online report · not medically verified

    150 µg · once per day · fasted before sleep

  • CJC-1295 no DAC · Week 5–8

    Online report · not medically verified

    200 µg · once per day · fasted before sleep

  • CJC-1295 no DAC · upper reports

    Online report · not medically verified

    200–300 µg · 1–3 times per day · not reliably established

More factsPeptide · Endocrine signals
Classification
Peptide · Endocrine signals
Research focus
Distinguished online from the DAC version and discussed for growth-hormone signalling; approval and confirmed safety are lacking.
Evidence
Preclinical
Status
Not FDA/EMA approved

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Schedule explained in detailCommunity/research information only

Amount status

Community source: 100–300 µg per administration, one to three times daily; not an approved or validated human dose.

Profile evidence level: preclinical.

Timing

Fasted windows and evening use are frequently cited. This is not a clinically confirmed standard.

No individual recommendation.

Cycle/duration

Community variants: 4–6 weeks with a 2–4 week break, 8–12 weeks with a 4–6 week break, or 5 days on/2 days off.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

Simple syringe and pen calculator

Choose your device and enter your known values. One result appears below.

You know the total solution volume. Calculate the scale mark for your entered amount.

Which syringe or pen?
More syringes
How much substance is in the vial?

Total amount on the label—not the container size in ml.

What is the total solution volume?

This is the total solution after dissolving, not automatically the water to add. Follow the specific product's instructions for preparation.

Which known amount do you want to convert?

Your known input. The calculator does not choose a suitable amount.

Complete the three number fields to see a result.

The calculator chooses neither a dose nor a mixing liquid. It does not check sterility, stability or suitability for use.

What the units mean
  • mg / µg = substance amount. 1 mg = 1,000 µg.
  • ml = liquid volume, not substance amount.
  • U / clicks = device markings. Their meaning depends on the device scale.
Calculation and extra figures

Complete the three number fields to see a result.

Scale and precision notes

Arithmetic does not establish measurement accuracy. Displayed numbers may be rounded; very small numbers use scientific notation. Intermediate values may not be readable on your device. Do not round fractional clicks up or down.

U-100 is used as a volume scale: 100 U = 1 ml. It is not the substance amount.

Copy this value from your pen's instructions. A 3 ml cartridge does not tell you the volume delivered at 60 clicks.

Source for the U-100 scale
Formulas and individual stepsOpen only if you want the deeper explanation.

Formulas used

  • Concentration (µg/ml) = vial mg × 1,000 ÷ fluid ml
  • Volume (ml) = target µg ÷ concentration
  • U-100 units = volume ml × 100

Mixing process described by the reference

01

Verify inputs

Independently check label, fluid, expiry information and planned volume. Do not use unclear or damaged products.

02

Disinfect stoppers

The reference calls for separate alcohol swabs and sterile single-use materials.

03

Add fluid slowly

The calculated fluid is described as running down the inside wall rather than being forced directly onto the powder.

04

Dissolve gently

The vial is rolled or swirled gently, not shaken, until no visible solids remain.

05

Inspect visually

Cloudy, discoloured or particle-containing solution is discarded. Clarity does not prove sterility or identity.

06

Label and store by product data

Record concentration and date. Reliable manufacturer or pharmacy information takes precedence.

An internet guide cannot ensure aseptic preparation. Bacteriostatic water, sterile water and approved product diluents are not interchangeable; benzyl alcohol may be unsuitable for some people.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

10 mg · assumed final volume: 3 ml

Community calculation example
Calculated amount100 µg
Concentration3,333.33 µg/ml
U-1003 U
Volume0.03 ml
Calculated amount200 µg
Concentration3,333.33 µg/ml
U-1006 U
Volume0.06 ml
Calculated amount300 µg
Concentration3,333.33 µg/ml
U-1009 U
Volume0.09 ml
All preparation informationProduct details and calculation examples from the available sources.

Pure reference arithmetic: 10 mg +3 ml =3,333 µg/ml; 100 µg =0.03 ml=3 U, 200 µg =6 U. Alternatively 10 mg +5 ml =2,000 µg/ml; 100 µg =5 U, 200 µg =10 U. Not a recommendation; 'no DAC' is often Mod-GRF(1-29) and is not equivalent to DAC-CJC-1295.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Shorter-acting GHRH analogue without the drug-affinity complex

CJC-1295 no DAC is classified as “Shorter-acting GHRH analogue without the drug-affinity complex”. Distinguished online from the DAC version and discussed for growth-hormone signalling; approval and confirmed safety are lacking. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

GHRH analogue

This examines whether a growth hormone-releasing hormone analogue prompts the pituitary gland to release its own growth hormone, like a signal instructing the gland to release. Researchers measure growth hormone and IGF-1 levels in blood.

02

Growth hormone signalling blend

This studies how several substances that each stimulate growth hormone release are combined by vendors, similar to pressing several buttons at once for the same effect. Individual agents are usually studied, not the combined product.

03

Growth-axis amplification

Researchers study how a substance amplifies the natural hormone chain from brain to pituitary to growth hormone, rather than supplying growth hormone directly. Hormone levels over time and muscle or fat mass are measured.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Bodybuilding forums

Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.

Anti-aging forums

Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Interference with GH, IGF-1 or other hormone axes may cause oedema, joint or nerve symptoms, glucose intolerance, blood-pressure and hormonal changes; dependable human data are absent for many research substances.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Active or previous malignancy, uncontrolled diabetes, intracranial disease, pregnancy/breastfeeding and hormone-sensitive disease require specialist assessment; approved products have specific contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • In medically justified use, IGF-1, fasting glucose/HbA1c, blood pressure, weight/oedema, thyroid and indication-specific hormones may be relevant; this is not a self-testing schedule.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

Approval and confirmed safety are lacking for both variants alike.

Clinical evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

Without the drug-affinity-complex binding, this variant acts markedly shorter than CJC-1295 with DAC.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

This profile is marked as WADA-relevant. Check the current Prohibited List and the specific sport or route in the original; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile